Croma Pharma GmbH

Leobendorf, Austria

Croma Pharma GmbH

Leobendorf, Austria
Time filter
Source Type

Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2011.1.2-2 | Award Amount: 11.03M | Year: 2012

The objective of the ALEXANDER project is the identification of novel strategies (e.g., proteolytic enzyme strategy, thiomer strategy, zeta potential changing systems, SNEDDS strategy) and the optimization of existing strategies (e.g., disulfide breaking strategy and slippery surface strategy) for the efficient transport of nanocarriers through the mucus gel layer (e.g., intestinal, nasal, ocular, vaginal, buccal, pulmonary). In particular, R&D activities will be focused on the synthesis of functionalized nanocarriers capable of permeating the mucus gel layer and delivering their therapeutic payload to the epithelium. The nanocarriers will be characterized with respect to their physicochemical properties, ability to cross the mucus gel layer, in vitro and in vivo cytotoxicity. The potential of the developed nanocarriers as delivery systems for mucosal administration of macromolecules will be demonstrated via the oral delivery of peptides, oligosaccharides and oligonucleotides and the nasal delivery of a plasmid encoding for an antigen.

PubMed | Institute fur Plastische Chirurgie Wien 19 GmbH, Medical University of Graz, Praxis Dr. Palatin and CROMA PHARMA GmbH
Type: | Journal: BioMed research international | Year: 2015

The dermal filler Princess VOLUME is a highly cross-linked, viscoelastic hyaluronic acid injectable gel implant used for aesthetic treatment. To evaluate the efficacy and safety of Princess VOLUME in the treatment of nasolabial folds, an open-label uncontrolled, multicenter study was conducted. Forty-eight subjects were recruited who had moderate to deep wrinkles, according to the Modified Fitzpatrick Wrinkle Scale (MFWS). Subjects received Princess VOLUME in both nasolabial folds at Day 0. Nasolabial fold severity was evaluated at 30, 90, 180, and 270 days after treatment, using the MFWS and the Global Aesthetic Improvement Scale (GAIS). Adverse events and treatment site reactions were recorded. Among the 48 subjects, 93.8% were female with a median age of 52 years. There were significant improvements (P < 0.0001) in the MFWS scores at 30, 180, and 270 days after treatment compared with those at baseline, with a mean decrease of 1.484 (0.408), 1.309 (0.373), and 1.223 (0.401), respectively; hence the primary endpoint was achieved and clinical efficacy demonstrated. Princess VOLUME was well tolerated, and most adverse events were injection site reactions of mild to moderate severity. Subject satisfaction (97.9%), subject recommendation of the treatment (93.6%), and investigators GAIS scores (97.9% improvement) were high.

Kuntner C.,AIT Austrian Institute of Technology | Wanek T.,AIT Austrian Institute of Technology | Hoffer M.,Croma Pharma GmbH | Dangl D.,Croma Pharma GmbH | And 4 more authors.
Molecular Imaging and Biology | Year: 2011

Purpose: The polysaccharide chitosan is a unique material for the design of ocular drug-delivery vehicles. The aim of this study was to radiolabel chitosan with iodine-124 ( 124I) for measurement of ocular pharmacokinetics in rabbits using small-animal positron emission tomography (PET). Procedures: Crl:CHBB (HM) rabbits received one drop (35 μL) of either a formulation containing chitosan (0.5%, w/v) spiked with 124I-labeled chitosan ([ 124I]chitosan) (n=4) or a control solution of sodium [ 124I]iodide in buffer (n=2) in the conjunctival sac of the right eye. Radioactivity distribution in the head region was measured at five different time points between 0 and 22 h after topical application. Regions of interest were manually defined in the reconstructed PET images, and activity concentration was quantified as percent applied dose (AD) per cubic centimeter tissue. Results: Clear differences were observed in the ocular pharmacokinetics of the two formulations. At 3 h after application, ocular activity uptake was 0.5±0.1%AD/cc for sodium [ 124I]iodide, compared to 4.7±5.3%AD/cc for the [ 124I]chitosan formulation. Conclusions: We were able to show that ocular pharmacokinetics of 124I-labeled ophthalmic formulations can be measured with small-animal PET and that [ 124I]chitosan had approximately a 2-fold increased ocular retention through the study period compared to sodium [ 124I]iodide. © Academy of Molecular Imaging and Society for Molecular Imaging, 2010.

Mateu B.P.,University of Natural Resources and Life Sciences, Vienna | Kainz B.,Croma Pharma GmbH | Pum D.,University of Natural Resources and Life Sciences, Vienna | Sleytr U.B.,University of Natural Resources and Life Sciences, Vienna | Toca-Herrera J.L.,University of Natural Resources and Life Sciences, Vienna
Methods and Applications in Fluorescence | Year: 2014

Fluorescence proteins are widely used as markers for biomedical and technological purposes. Therefore, the aim of this project was to create a fluorescent sensor, based in the green and cyan fluorescent protein, using bacterial Slayers proteins as scaffold for the fluorescent tag. We report the cloning, expression and purification of three Slayer fluorescent proteins: SgsEEGFP, SgsEECFP and SgsE13aaECFP, this last containing a 13amino acid rigid linker. The pH dependence of the fluorescence intensity of the Slayer fusion proteins, monitored by fluorescence spectroscopy, showed that the ECFP tag was more stable than EGFP. Furthermore, the fluorescent fusion proteins were reassembled on silica particles modified with cationic and anionic polyelectrolytes. Zeta potential measurements confirmed the particle coatings and indicated their colloidal stability. Flow cytometry and fluorescence microscopy showed that the fluorescence of the fusion proteins was pH dependent and sensitive to the underlying polyelectrolyte coating. This might suggest that the fluorescent tag is not completely exposed to the bulk media as an independent moiety. Finally, it was found out that viscosity enhanced the fluorescence intensity of the three fluorescent Slayer proteins. © 2014 IOP Publishing Ltd.

Brezna W.,Integrated Microsystems Austria | Dragostinoff N.,Integrated Microsystems Austria | Prinz M.,Croma Pharma GmbH
IFAC Proceedings Volumes (IFAC-PapersOnline) | Year: 2012

Accurate eye models representing the anatomic and optical behavior of the real human eye are essential for the design and development of implantable intraocular lenses (IOLs) for cataract surgery. The correct prediction of the IOL's dioptric power is of high importance, as a wrongly chosen IOL dioptric power outpaces every other known aberration in loss of visual acuity. An introduction into eye modeling is given encompassing biometric data acquisition, 4 modeling paradigms (population basedand personalized eye modeling, models for IOL power calculation and discrete, physical eye models) and the description of some modeling procedures. Finally, field tracing simulations of a trifocal diffractive IOL in different eye models (Navarro model, Liou-Brennan model and ISO eye model) are compared. It is concluded that the ISO eye model will have to be substituted by a more realistic model in cases where the addition value of a multifocal IOL is to be obtained correctly by measurements. © 2012 IFAC.

Thiomatrix Forschungs Und Beratungs Gmbh and Croma Pharma Gmbh | Date: 2015-02-12

Because of the formation of disulfide bridges with mucus glycoproteins, the mucoadhesive properties of polymeric compounds can be significantly improved by the covalent attachment of thiol substructures to them. By the transformation of free thiol groups on such polymers in disulfides with mercaptonicotinamides or mercaptopyridoxins these thiol groups become comparatively more reactive resulting in significantly improved mucoadhesive properties. Furthermore, polymers exhibiting disulfide partial structures with mercaptonicotinamides or mercaptopyridoxins do not need to be protected against oxidation. In addition, they show comparatively higher permeation enhancing properties.

Croma Pharma Gmbh | Date: 2010-08-12

A method for producing a container welded in a protective wrapping, which contains a viscoelastic fluid for use as eye drops in the chirurgical treatment of eyes, wherein the container is configured such that the fluid may be removed from the container via a predetermined breaking point, characterized by the combination of the measures that the viscoelastic fluid is filled into the container, which is thereupon closed, the closed container is welded into a protective wrapping, whereupon the welded container including the protective wrapping is subjected to thermal sterilization.

The invention relates to the use of an aqueous viscoelastic fluid for producing a medicinal product for the surgical treatment of the eye, which fluid produces an optical magnifying effect of the lens and the pupil upon application onto the surface of the eye from a single-dose receptacle. The viscoelastic fluid comprises at least one viscosity-increasing, physiologically acceptable polymer selected from the group consisting of hydroxypropylmethyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hyaluronic acid, sodium alginate, hydroxylpropyl guar polyvinylpyrrolidone, polyvinyl alcohol, polymethacrylic acid (carbomer), polyoxyethylene polyoxypropylene copolymer (poloxamer) and polyethylene glycol, at a concentration of 0.01-30%.

PubMed | Danube University Krems and Croma Pharma GmbH
Type: Journal Article | Journal: Cartilage | Year: 2016

An important feature of biomaterials used in cartilage regeneration is their influence on the establishment and stabilization of a chondrocytic phenotype of embedded cells. The purpose of this study was to examine the effects of a porous 3-dimensional scaffold made of cross-linked hyaluronic acid on the expression and synthesis performance of human articular chondrocytes.Osteoarthritic chondrocytes from 5 patients with a mean age of 74 years were passaged twice and cultured within the cross-linked hyaluronic acid scaffolds for 2 weeks. Analyses were performed at 3 different time points. For estimation of cell content within the scaffold, DNA-content (CyQuant cell proliferation assay) was determined. The expression of chondrocyte-specific genes by embedded cells as well as the total amount of sulfated glycosaminoglycans produced during the culture period was analyzed in order to characterize the synthesis performance and differentiation status of the cells.Cells showed a homogenous distribution within the scaffold. DNA quantification revealed a reduction of the cell number. This might be attributed to loss of cells from the scaffold during media exchange connected with a stop in cell proliferation. Indeed, the expression of cartilage-specific genes and the production of sulfated glycosaminoglycans were increased and the differentiation index was clearly improved.These results suggest that the attachment of osteoarthritic P2 chondrocytes to the investigated material enhanced the chondrogenic phenotype as well as promoted the retention.

O UNIVERSKIN - é um tratamento dermatológico prsonalizado, de base científica e fornecido pelo médico, que supera os cuidados com a pele e a dermatologia funcional. O UNIVERSKIN um produto dermatológico é usado com grande êxito por dermatologistas, cirurgiões plásticos e profissionais de estética em 23 países em todo o mundo. Com o objetivo de expandir ainda mais as suas atividades comerciais na área dos tratamentos dermatológicos, a Croma-Pharma GmbH da Austria assinou um contrato abrangente de licenciamento e de distribuição com a UNIVERSKIN SAS de França. Segundo muitos especialistas desta área, o UNIVERSKIN é o conceito mais inovador e personalizado de cuidados da pele, disponível atualmente no mercado. O UNIVERSKIN já é hoje usado com grande êxito por mais de 500 dermatologistas em França e por dermatologistas em 23 países em todo o mundo. A cooperação foi acordada para, pelo menos, 8 anos. Os direitos exclusivos de licenciamento e de distribuição para todos os produtos UNIVERSKIN referem-se aos países europeus, nomeadamente a Alemanha, Austria, França, Polónia, Espanha, Portugal, Holanda e territórios ultramarinos como a Austrália, o Canadá e o Brasil. Pelas licenças e os direitos de distribuição a Croma-Pharma pagou uma quantia não revelada, na ordem de vários milhões de euros. O acordo entra em vigor a 1 de Janeiro de 2017. Sob a sua marca premium Princess®, que está disponível apenas através de dermatologistas e em farmácias, a Croma Pharma oferece uma gama alargada de produtos na área da medicina estética não invasiva e minimamente invasiva. A gama inclui produtos baseados no Ácido Hialurónico como preenchimentos intradérmicos, fios de sustentação, máscaras faciais, serums e a série True Hyaluron. Atualmente, estão a ser levados a cabo estudos na Europa e nos EUA para aprovação do novo produto de Neurotoxina Botulínica da Croma, que se espera seja aprovado em 2019. Para os médicos, a Croma oferece todos os tratamentos dermatológicos relevantes, a partir de uma só fonte na aclamada qualidade «Made in Austria» («one-stop-shop»). A gama estética da linha de produtos Princess® é desenvolvida e fabricada pela Croma-Pharma GmbH na sede da empresa em Leobendorf próximo de Viena, Austria. O Dr. Charalampos Arampatzis, CEO e coproprietário da UNIVERSKIN SAS disse. «Graças a esta promissora colaboração com a Croma-Pharma, estamos a melhorar a nossa estrutura de vendas em mercados importantes e a melhorar significativamente a atividade comercial da UNIVERSKIN através da reconhecida especialização da empresa familiar, orientada para a inovação, Croma-Pharma». Mag.Pharm. Andreas Prinz, CEO e coproprietário da Croma-Pharma GmbH afirmou: «Com a UNIVERSKIN, conseguimos implementar o conceito mais inovador na área dos cuidados dermatológicos personalizados e juntar ao nosso portfolio um sistema único de formação clínica. Ao fazê-lo, a Croma-Pharma destaca a sua posição de liderança como inovadora no campo da medicina estética não invasiva e minimamente invasiva». A UNIVERSKIN é uma empresa privada pioneira na área da dermatologia, criada em 2006 e sediada em Sophia Antipolis, França. A equipa fundadora e gestora da UNIVERSKIN é constituída por dermatologistas, cirurgiões plásticos, farmacêuticos, biólogos, químicos e anatomopatologistas. A UNIVERSKIN investe massivamente em investigação e desenvolvimento para revolucionar os cuidados dermatológicos e possibilitar aos médicos pensarem mais na pele do que no produto: um regresso à simplicidade para o médico e mais eficácia e tolerância para o utilizador. A UNIVERSKIN aporta uma lógica clínica ao cuidado da pele: a análise da pele realizada por médicos experientes, a escolha dos ingredientes ativos, a concentração, a duração da aplicação e depois a monitorização. Pela primeira vez, o médico pode delinear um cuidado dermatológico minimalista, clinicamente comprovado que apresenta resultados apenas com um produto. Para criar a fórmula para cada paciente, é realizada uma análise clínica da pele efetuada por médicos especialistas, que permite a escolha dos ingredientes ativos importantes entre 19 ingredientes ativos disponíveis, desenvolvidos e produzidos em França após 8 anos de investigação. O médico irá escolher os princípios ativos e a concentração e os pacientes escolherão a textura. São possíveis até 1159 fórmulas, em 57 concentrações diferentes. Com um tempo de preparação de menos de dois minutos, a fórmula de cuidados dermatológicos será composta sob controlo do médico e à frente do paciente. Irá sendo aperfeiçoada ao longo do tempo para condizer com o estilo de vida, a idade, o estado da pele do paciente e as agressões ambientais e sazonais. Sobre a Croma-Pharma GmbH: Fundada em 1976, a Croma-Pharma é uma empresa farmacêutica com uma atividade global, propriedade de uma família, sediada em Leobendorf, Áustria. A Croma-Pharma é uma das empresas mais inovadoras no mercado crescente de medicina estética minimamente invasiva (MIAM). Sob a sua marca premium Princess® a Croma oferece máscaras faciais, serums, preenchimentos intradérmicos e fios de sustentação. Estes produtos de alta qualidade são distribuídos exclusivamente por médicos e farmácias. Com a produção anual de 6 milhões de seringas previamente enchidas e mais de 150 milhões de seringas desde a sua criação, a Croma-Pharma é um produtor líder de produtos baseados no Ácido Hialurónico. O êxito baseia-se na investigação e no desenvolvimento na sede da empresa em Leobendorf, Áustria. O Conselho de Administração da Croma tem uma visão clara para as tecnologias de alta qualidade e agarra corajosamente oportunidades de licenciamento interno ou de aquisições de empresas complementares. A Croma-Pharm emprega atualmente 310 pessoas e explora 11 subsidiárias. Através de parcerias de distribuição, os produtos são comercializados em mais de 70 países. A Croma-Pharma é uma empresa premiada e celebrou o quadragésimo aniversário em 2016.

Loading Croma Pharma GmbH collaborators
Loading Croma Pharma GmbH collaborators